Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.

Saved in:
Bibliographic Details
Title: Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.
Authors: Kohli MA; Michele A. Kohli (michele.kohli@optum.com) is a director of health economics and outcomes research at Optum in Burlington, Ontario., Farkouh RA; Raymond A. Farkouh is senior director of outcomes research at Pfizer Vaccines Inc., in Collegeville, Pennsylvania., Maschio MJ; Michael J. Maschio is a lead analyst for health economics and outcomes research at Optum in Ontario., McGarry LJ; Lisa J. McGarry is a director of health economics and outcomes research at Ariad Pharmaceuticals Inc., in Cambridge, Massachusetts. At the time of this study, she was a director of health economics and outcomes research at Optum in Boston, Massachusetts., Strutton DR; David R. Strutton is a vice president of outcomes research at Merck in North Wales, Pennsylvania. At the time of this study, he was a vice president of global health and value at Pfizer Inc., Weinstein MC; Milton C. Weinstein is the Henry J. Kaiser Professor of Health Policy and Management at the Harvard T.H. Chan School of Public Health, in Boston.
Source: Health affairs (Project Hope) [Health Aff (Millwood)] 2015 Jul; Vol. 34 (7), pp. 1234-40.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Project Hope Country of Publication: United States NLM ID: 8303128 Publication Model: Print Cited Medium: Internet ISSN: 2694-233X (Electronic) Linking ISSN: 02782715 NLM ISO Abbreviation: Health Aff (Millwood) Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2694-233X
DOI:10.1377/hlthaff.2014.1274